13th Dec 2016 15:32
Cyprotex PLC
("Cyprotex" or "the Company")
Director Dealing
Cyprotex PLC (AIM: CRX), a specialist Contract Research Organisation, announces that it was notified on 12 December 2016 that, on 8 December 2016, John Dootson, Chief Financial Officer, transferred 36,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from an account in his own name to his wife Sandra Dootson for nil consideration by way of a gift. Following this transfer, John Dootson's' beneficial interest in the Company's Ordinary Shares remains unchanged at 68,928 Ordinary Shares, representing 0.31% of the Company's total issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| John Kevin Dootson | ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Director of Cyprotex PLC | ||||||
b)
| Initial notification /Amendment
| Initial Notification | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| Cyprotex PLC | ||||||
b)
| LEI
| N/A | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 1p each
ISIN Code: GB00BP25RZ14
| ||||||
b)
| Nature of the transaction
| Transfer of Ordinary Shares | ||||||
c)
| Price(s) and volume(s)
|
| ||||||
d)
| Aggregated information
- Aggregated volume
- Price
| N/A | ||||||
e)
| Date of the transaction
| 08/12/2016 | ||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | www.cyprotex.com |
N+1 Singer (Nomad & Broker) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jen Boorer
| www.n1singer.com |
Notes to Editors
About Cyprotex PLC
Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com
Related Shares:
CRX.L